Dan Nardi shares how Reimagine Care uses AI triage and connected devices to scale outpatient cancer support, enabling faster, personalized symptom monitoring.
|Videos|October 21, 2021
- MHE October 2021
- Volume 31
- Issue 10
Shantanu Nundy Shares Having the Opportunity to Get "Direct Impact at Scale" at Accolade is Something He's Grateful For
Author(s)Briana Contreras
Shantanu Nundy, M.D., MBA, chief medical officer at Accolade, is one of the emerging health leaders featured in the October 2021 issue of Managed Healthcare Executive. In this video he talks about the career achievement that has given him the greatest satisfaction and who has had the greatest influence in his life, which are his parents, sister and aunt and uncle.
Advertisement
Articles in this issue
almost 5 years ago
Emerging Health Leaders: Sonia Samagh of Stealth Venturealmost 5 years ago
Emerging Health Leaders: Andrew Toy, M.S., of Clover Healthalmost 5 years ago
Emerging Health Leaders: Evie Powell, Ph.D., of Proprioalmost 5 years ago
Emerging Health Leaders: Michael Palantoni of AthenahealthAdvertisement
Related to this article
In this interview, Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, discuss their study, which found a 16.8% increase in HIV incidence rates among Hispanic populations in antisanctuary counties after 2018 immigration policy shifts.
Metabolic dysfunction-associated steatotic liver disease (MASLD) may differ biologically from obesity-linked MASH, a mouse study suggests, with salt driving liver inflammation without obesity.
In this discussion, Ohio State economist Eric Seiber, Ph.D., explains how inconsistent claims-data definitions can skew estimates of first-episode psychosis and why standardization matters for early treatment and sustainable payment models.
CMS’ mandatory GLOBE drug model ties some Medicare Part B rebates to global prices, but cuts projected savings sharply amid shifting Part D premiums.
Bill Kerr of Avalon Heath Solutions says incorporating Z codes into CPT codes for lab and genetic testing would add needed specificity, reduce waste and possibly head off fraud.
States have to turn that information into medical frailty determinations that are clinically credible, consistent, and workable across large Medicaid populations.
A meta-analysis found steatotic liver disease in 75% of patients with sleep-disordered breathing and that CPAP lowered liver enzymes but not liver fat.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Closing the outpatient monitoring gap in cancer
2
A conversation with Eric Seiber, Ph.D., about why defining first-episode psychosis matters
3
A conversation with Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, about the relationship between HIV incidence in Hispanic communities and immigration policy
4
New lean MASH mouse model could guide more targeted liver disease treatment in humans
5